TrialBreast cancer research : BCR2019

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).

Tejal A Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.